The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
|Articles|October 6, 2015
Be Part of the Conversation by Joining Tweet Chat
The second day of CPhI Worldwide will host an industry wide tweet chat broadcasting a conversation between the CPhI expert panelists and the attendees.
Advertisement
The second day of CPhI Worldwide will host an industry wide tweet chat #CPhIChat broadcasting a conversation between the CPhI expert panelists and the attendees.
With the release of the CPhI 2015 annual report, attendees will be able to analyze the contributions of the panelists and contribute to a live discussion displayed throughout the screens at the show.
#CPhIChat will take place on Wednesday 14 October, from 2 to 4 pm. The entire industry is encouraged to log into Twitter to join the debate by using the hashtags #CPhIChat and #CPhIWW.
Attendees can follow the debate in real-time on the display screens that will be set-up throughout the exhibition. Alternatively, the debate can be followed by searching for the hashtags on Twitter from anywhere in the world. A summary report will be released after the show.
Advertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement